[HTML][HTML] Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer
M Yu, H Wang, W Zhao, X Ge, W Huang, F Lin… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Oxaliplatin is a widely used chemotherapy drug for advanced colorectal cancer
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer
M Yu, H Wang, W Zhao, X Ge, W Huang… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Rationale: Oxaliplatin is a widely used chemotherapy drug for advanced colorectal cancer
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer.
M Yu, H Wang, W Zhao, X Ge, W Huang, F Lin… - Theranostics, 2022 - europepmc.org
Rationale: Oxaliplatin is a widely used chemotherapy drug for advanced colorectal cancer
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
[PDF][PDF] Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer
M Yu, H Wang, W Zhao, X Ge, W Huang, F Lin, W Tang… - pdfs.semanticscholar.org
Rationale: Oxaliplatin is a widely used chemotherapy drug for advanced colorectal cancer
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …
(CRC) and its resistance is a major challenge for disease treatment. However, the molecular …